Protein-Losing Enteropathy Resolved by Helicobacter pylori Eradication
Bruno Sousa1, Rosa Alves1, Catarina Pestana Santos1
1Department of Internal Medicine, Hospital Garcia de Orta, Almada, Lisbon, Portugal.
Protein-losing enteropathy (PLGE) can cause edema and low protein levels. This case study shows that Helicobacter pylori infection can cause PLGE, and eradication therapy resolved the condition.
Area of Science:
- Gastroenterology
- Internal Medicine
- Infectious Diseases
Background:
- Protein-losing enteropathy (PLGE) is a rare condition characterized by excessive gastrointestinal protein loss.
- Symptoms include hypoproteinemia and edema, often with multifactorial causes.
Purpose of the Study:
- To investigate the potential link between Helicobacter pylori infection and protein-losing enteropathy.
- To present a case study of PLGE successfully treated by H. pylori eradication.
Main Methods:
- A case report of a 24-year-old male with edema and secretory diarrhea.
- Diagnostic workup excluded liver disease and proteinuria.
- Upper endoscopy revealed chronic H. pylori gastritis.
Main Results:
- The patient presented with hypoproteinemia and iron deficiency anemia.
- H. pylori eradication therapy led to complete resolution of clinical and laboratory abnormalities.
- This suggests H. pylori as a potential cause of PLGE.
Conclusions:
- Protein-losing enteropathy can be associated with Helicobacter pylori infection.
- Eradication of H. pylori may resolve PLGE and its related symptoms.
More Related Videos
05:23Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
03:47Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
Published on: November 1, 2024
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...